The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global hemostasis and tissue sealing agents market size reached US$ 5.92 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 9.28 Billion by 2027, exhibiting a growth rate (CAGR) of 7.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Hemostasis is a normal physiological response of the body, which regulates blood fluidity by stopping blood loss from the damaged blood vessel through hemostats. On the other hand, tissue sealing prevents perioperative hemorrhage and controls blood loss from damaged tissues through tissue sealing agents. Hemostats and tissue sealing agents are both used to compress blood vessels and avoid hemorrhage, blood flow, and other fluid discharge. They include thrombin sealant, fibrin glue, bovine serum or albumin, and gelatin matrix. They ensure blood fluidity and blood vessel integrity and help reduce wound healing and operative time, minimize the recovery time and hospital stay and provide better management of anticoagulated patients. They are used to disperse raw surface bleeding, bone bleeding, oozing venous bleeds, and needle-opening bleeding. At present, they are easily available in the market with varying compositions, mechanisms of action, cost, application, and adherence.
The increasing global geriatric population and chronic medical conditions represent one of the key factors positively influencing the market. The rising participation of individuals in physical activities, along with the increasing occurrence of injuries caused during workouts and sports and physical activities, is catalyzing the demand for hemostasis and tissue sealing agents across the globe. In addition, rising cases of road accidents and gastrointestinal, pulmonary, and cardiovascular surgeries are increasing the demand for hemostats and tissue sealing. Apart from this, shifting consumer preference toward minimally invasive surgeries (MIS) for minimal incision and blood loss and faster recovery time is offering lucrative growth opportunities to manufacturers. Furthermore, leading market players are focusing on the development of multi-usage and ready-to-use products, which is expected to propel market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemostasis and tissue sealing agents market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, material type, application and end user.
Breakup by Product Type:
Breakup by Material Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advance Medical Solution Group Plc., Artivion Inc., B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson & Company, Integra LifeSciences Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Smith & Nephew plc and Terumo Corporation.
|Base Year of the Analysis||2021|
|Segment Coverage||Product Type, Material Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Advance Medical Solution Group Plc., Artivion Inc., B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson & Company, Integra LifeSciences Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Smith & Nephew plc and Terumo Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at